2025 North America Antisense And Rnai Therapeutics Market Revenue Opportunities Report
Description
The 2025 North America Antisense And Rnai Therapeutics Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antisense and RNAi therapeutics market in North America are Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, and GSK plc. Ionis Pharmaceuticals is a pioneer in antisense technology with multiple FDA-approved drugs targeting neurological and rare diseases. Alnylam Pharmaceuticals focuses heavily on RNA interference therapeutics and has ongoing collaborations to expand delivery technologies. Sarepta Therapeutics specializes in RNA-targeted treatments for rare genetic disorders such as Duchenne muscular dystrophy. GSK plc, a global pharmaceutical leader, invests significantly in RNAi technologies and partnerships to accelerate RNA-based drug development.
These companies benefit from North America's robust healthcare infrastructure, strong R&D support, and favorable regulatory environment, allowing rapid advancement and commercialization of RNA-based therapies. The region commands over 40% of the global market share, driven by a high prevalence of genetic and neurodegenerative diseases and substantial government and private investments. Product approvals like Ionis's Wainua and Alnylam's ONPATTRO validate the market's clinical progress. Strategic collaborations, such as GSK's partnership with Wave Life Sciences, further enhance innovation and delivery platforms in the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antisense and RNAi therapeutics market in North America are Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, and GSK plc. Ionis Pharmaceuticals is a pioneer in antisense technology with multiple FDA-approved drugs targeting neurological and rare diseases. Alnylam Pharmaceuticals focuses heavily on RNA interference therapeutics and has ongoing collaborations to expand delivery technologies. Sarepta Therapeutics specializes in RNA-targeted treatments for rare genetic disorders such as Duchenne muscular dystrophy. GSK plc, a global pharmaceutical leader, invests significantly in RNAi technologies and partnerships to accelerate RNA-based drug development.
These companies benefit from North America's robust healthcare infrastructure, strong R&D support, and favorable regulatory environment, allowing rapid advancement and commercialization of RNA-based therapies. The region commands over 40% of the global market share, driven by a high prevalence of genetic and neurodegenerative diseases and substantial government and private investments. Product approvals like Ionis's Wainua and Alnylam's ONPATTRO validate the market's clinical progress. Strategic collaborations, such as GSK's partnership with Wave Life Sciences, further enhance innovation and delivery platforms in the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
